Medicascy Artificial Intelligence Solutions Platform is a new technology that uses artificial intelligence to predict, in just a few weeks, where ingredients will have significant impact, cutting research and development time while improving the product.
Medicascy Artificial Intelligence Solutions Platform (MedicascyAI), from efficacyAI (Dillsburg, PA) is a new technology that uses artificial intelligence to predict, in just a few weeks, where ingredients will have significant impact, cutting research and development time while improving the product. The technology intends to reduce the nutraceutical industry’s reliance on secondary science, and guide primary research toward more successful results. This $43 million, scientifically proven technology has documented results in more than 50 major peer-reviewed papers and has also been recognized by receiving awards from the National Institutes of Health (NIH).
MedicascyAI screens the interactions of molecules with every human protein to help determine how specific plant-based molecules may benefit health, as well as any potential adverse effects. This is a process that typically requires years and millions of dollars in research. “Artificial intelligence is accelerating this process while reducing costs and improving outcomes with more science behind it,” said Jeffrey Skolnick, PhD, chairman of scientific Board and chief innovation officer for efficacyAI, in a press release. “Results come in weeks, not years, and are accompanied by carefully calibrated confidence indices (CIs).
CIs predict the probability that the prediction is correct and have been validated through subsequent experiments. Skolnick says that MedicascyAI has already analyzed over 1,475 GRAS molecules and 300,000 natural compounds, estimating that the AI’s algorithm covers about 97% of all proteins and can make reliable predictions for about 40% of molecules found in natural products.
“There is significant latent demand for non-drug solutions,” Skolnick explains. “But the dietary supplement industry’s pricing model doesn’t support the type of due diligence used by pharma. MedicascyAI speeds up certainty with less overall cost by using a set of sophisticated algorithms that analyze compounds for safety and efficacy in relation to the biological processes that jeopardize good health.”
“MedicascyAI can be used to create effective new products and identify potential new uses for existing branded products. It can also analyze current products for safety and efficacy. All we need is the chemical structure,” says efficacyAI chairman and CEO Tony Bellezza. “This is also an excellent starting point if you want to create a new product that focuses on a specific health benefit.”